117 S3974 IS: Ending Discrimination in COVID–19 Treatments Act U.S. Senate 2022-03-31 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II117th CONGRESS2d SessionS. 3974IN THE SENATE OF THE UNITED STATESMarch 31, 2022Mr. Cruz introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILLTo prohibit the consideration of patients' race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, or political ideology or speech in determining eligibility for monoclonal antibody doses distributed by the Federal Government.

1.

Short title

This Act may be cited as the Ending Discrimination in COVID–19 Treatments Act.

2.

Eligibility to receive monoclonal antibody treatment

The Secretary of Health and Human Services shall require States, as a condition for receipt of monoclonal antibody doses from the Federal Government, to ensure that providers receiving distributions of such monoclonal antibody doses from such States do not take into consideration the race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, or political ideology or speech of a patient in determining whether a patient is eligible to receive such treatment.